Development of Reduced Vancomycin Susceptibility in Methicillin-Susceptible Staphylococcus aureus

Clinical Infectious Diseases, Oct 2009

Background. Most cases of reduced vancomycin susceptibility in Staphylococcus aureus reported in the literature have been in methicillin-resistant strains. We report the development of reduced vancomycin susceptibility in a series of clonally related, methicillin-susceptible S. aureus (MSSA) clinical isolates. This isogenic series permitted us to determine whether the evolution of reduced vancomycin susceptibility in MSSA is similar to that seen in MRSA. Methods. Differences in vancomycin population analysis profiles; chemical autolysis; vancomycin, oxacillin, and daptomycin minimum inhibitory concentrations; and bactericidal activities were examined. Results. Progressive vancomycin resistance correlated with increasing daptomycin nonsusceptibility. Chemical autolysis and the bactericidal activity of vancomycin, oxacillin, and daptomycin were reduced in the final, vancomycin-intermediate S. aureus isolate, compared with the vancomycin-susceptible MSSA progenitor. Conclusions. Clinicians should recognize that reduced vancomycin susceptibility can occur in S. aureus irrespective of background methicillin susceptibility and that development of intermediate vancomycin susceptibility in MSSA may result in increased tolerance to several classes of anti-staphylococcal antibiotics.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://cid.oxfordjournals.org/content/49/8/1169.full.pdf

Development of Reduced Vancomycin Susceptibility in Methicillin-Susceptible Staphylococcus aureus

CID Development of Reduced Vancomycin Susceptibility in Methicillin-Susceptible Staphylococcus aureus Satish K. Pillai () 0 1 2 Christine Wennersten 1 2 Lata Venkataraman 1 2 George M. Eliopoulos 0 1 2 Robert C. Moellering 1 Jr 0 1 2 Adolf W. Karchmer 0 1 2 0 Harvard Medical School , Boston, Massachusetts 1 Received 2 February 2009; accepted 28 May 2009; electronically published 21 September 2009. Center, Div of Infectious Diseases , 110 Francis St, Suite GB, Boston, MA 02215 2 Division of Infectious Diseases , Beth Israel Deaconess Medical Center Background. Most cases of reduced vancomycin susceptibility in Staphylococcus aureus reported in the literature have been in methicillin-resistant strains. We report the development of reduced vancomycin susceptibility in a series of clonally related, methicillin-susceptible S. aureus (MSSA) clinical isolates. This isogenic series permitted us to determine whether the evolution of reduced vancomycin susceptibility in MSSA is similar to that seen in MRSA. Methods. Differences in vancomycin population analysis profiles; chemical autolysis; vancomycin, oxacillin, and daptomycin minimum inhibitory concentrations; and bactericidal activities were examined. Results. Progressive vancomycin resistance correlated with increasing daptomycin nonsusceptibility. Chemical autolysis and the bactericidal activity of vancomycin, oxacillin, and daptomycin were reduced in the final, vancomycin-intermediate S. aureus isolate, compared with the vancomycin-susceptible MSSA progenitor. Conclusions. Clinicians should recognize that reduced vancomycin susceptibility can occur in S. aureus irrespective of background methicillin susceptibility and that development of intermediate vancomycin susceptibility in MSSA may result in increased tolerance to several classes of anti-staphylococcal antibiotics. - Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of community and nosocomial infections. Treatment with vancomycin has been the standard of care for serious MRSA infection for 140 years. However, over the past decade there have been reports of vancomycin treatment failures for MRSA infection [1–3]. True vancomycin-resistant S. aureus (VRSA; defined as a minimum inhibitory concentration [MIC] of 16 mg/mL [4]), which is associated with the incorporation of the enterococcal vanA cassette into S. aureus, has been reported only sporadically [5]. In addition to VRSA, reduced vancomycin susceptibility (RVS) is seen among vancomycin-intermediate S. aureus (VISA; MIC of 4–8 mg/mL) and hetero-VISA (susceptible to vancomycin by routine susceptibility testing, but containing resistant subpopulations with MICs 4 mg/mL) [4, 6]. Development of hetero-VISA and/or VISA does not involve incorporation of the vanA cassette, is associated with altered expression of multiple regulatory genetic elements, and is phenotypically characterized by increased cell wall thickness, altered cell wall penicillinbinding protein profiles, and reduced rates of cell wall autolysis [7–13]. Decreasing vancomycin susceptibility is a predictor of failing vancomycin therapy [2, 3, 14]. Most reported cases of hetero-VISA and VISA have arisen from MRSA progenitors. There are few detailed reports of RVS in methicillin-susceptible isolates [15– 17]. In fact, in some of these cases the methicillinsusceptible S. aureus (MSSA) with RVS may have arisen from MRSA backgrounds. For instance, in 1 report of MSSA-RVS, molecular investigation revealed the presence of the genetic element conveying methicillin-resistance, mecA, and the authors demonstrated an inverse correlation between oxacillin and vancomycin MICs in the series of S. aureus isolates recovered from the index patient [15]. A similar inverse correlation between oxacillin and vancomycin MICs has been reported in other mecA-positive S. aureus isolates [18]. In another case, the source patient harbored genetically related methicillin-resistant and methicillin-susceptible Table 1. Antibiotic Susceptibility Results (Agar and Macro-Broth Dilution) for Study Isolates Minimum inhibitory concentration, mg/mL Vancomycin (agar) Oxacillin (agar) Daptomycin (broth) VISA, and the authors postulated that the methicillin-susceptible VISA arose from deletion of the mecA element [16]. BobinDebruex et al [17] described the clinical recovery of a mecAnegative, methicillin-susceptible hetero-VISA isolate; however, there was no vancomycin-susceptible progenitor to serve as a comparator. In this study, we investigated a series of clinical MSSA isolates recovered from a patient who experienced vancomycin therapy failure (case 12 in Table 1 from reference [6]). Briefly, a patient with an infected foot ulcer initially completed a 2-week course of antibiotic therapy with oxacilllin for MSSA bacteremia without evidence of remote sites of infection. The patient, complaining of back pain, returned 3 weeks after the original bacteremia and was found to have vertebral osteomyelitis, fo (...truncated)


This is a preview of a remote PDF: https://cid.oxfordjournals.org/content/49/8/1169.full.pdf

Satish K. Pillai, Christine Wennersten, Lata Venkataraman, George M. Eliopoulos, Robert C. Moellering Jr, Adolf W. Karchmer. Development of Reduced Vancomycin Susceptibility in Methicillin-Susceptible Staphylococcus aureus, Clinical Infectious Diseases, 2009, pp. 1169-1174, 49/8, DOI: 10.1086/605636